Mark Carvlin, PhD, Chief Operating Officer, PreventAGE
Mark Carvlin, Ph.D., is a seasoned veteran of the life sciences industry serving as an entrepreneur, venture capitalist, consultant, and executive. Previously, he has served as Chief Operating Officer (COO) of CardioVax, a cardiovascular drug development firm, and COO and Vice President, Clinical Affairs for Atherochem and Nanoscan Imaging, two development-stage companies. Mark held positions of Venture Partner and General Partner in Mi3 Venture Partners, a venture capital fund pursuing early-stage investments in life science technologies. In addition, he is a founding partner in SWGC Life-Sciences, a strategic management consulting company. Before pursuing entrepreneurial activities, Mark spent 10 years in the pharmaceutical industry advancing in business development, clinical development, strategic management, marketing, medical services and planning, and government and business affairs with Bracco Diagnostics Inc. and Bristol-Myers Squibb. Dr. Carvlin has been a member of the Radiology Departments of Georgetown University and the University of Pennsylvania. He has served as the principal investigator on a number of Phase 2, Phase 3, and Phase 4 clinical trials and has co-authored over 125 scientific publications. Dr. Carvlin received his Ph.D. in Biophysics from Roswell Park Cancer Institute.